Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LI
Liminatus Pharma, Inc. Class A Common Stock
LIMN
Volume
16.70K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
LI
LIMN
LI
Liminatus Pharma, Inc. Class A Common Stock
LIMN
News
·
Liminatus Pharma Announces Nasdaq Delisting Notification
Mkt Cap
$4.3M
Volume
16.70K
Next Earnings
November 12th
Chart
Earnings
News
About
Insider
Filings
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma (LIMN) received a delisting notice from Nasdaq on May 20, 2026, after failing to meet minimum market value requirements ($50M MVLS and $15M MVPHS) within the 180-day compliance period. The company intends to appeal the decision before the Nasdaq Hearings Panel by May 27, 2026, which will stay any suspension pending the hearing.
GlobeNewswire Inc. · May 22, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma announced a definitive merger agreement with InnocsAI LLC, a biotechnology company specializing in CAR-T and antibody-based oncology therapies. Under the agreement, InnocsAI members will receive 1.6 billion shares of Liminatus common stock at $0.20 per share, valuing the transaction at approximately $320 million. The merger aims to expand Liminatus' oncology pipeline with advanced cell therapy assets including IBC101 (bivalent CAR-T for B-cell malignancies) and INC101 (dual-antigen CAR-T for solid tumors), pending shareholder and regulatory approvals.
Benzinga · May 21, 2026
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
Liminatus Pharma (LIMN) shares surged 79.34% to $0.34 in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal brings a clinical-stage oncology portfolio including CAR-T and solid tumor programs. However, the stock has declined 96.95% over the past 12 months and trades near its 52-week low, with technical indicators showing negative price trends across all timeframes.
Benzinga · May 21, 2026
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Liminatus Pharma (NASDAQ: LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of a public offering of 13.8 million shares and warrants at $0.29 per share, expected to raise approximately $4.0 million in gross proceeds. The offering is expected to close on February 18, 2026, with net proceeds to be used for working capital and advancement of the company's CD47-blockade therapeutic programs.
Benzinga · Feb 17, 2026
Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Liminatus Pharma, a clinical-stage immuno-oncology company, has entered a Memorandum of Understanding with Capital Trust Group for a $30 million equity investment to support its research and development of advanced immunotherapy assets.
Benzinga · Oct 27, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
LI
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Buy
Sell
Market
Limit
Soon
LIMN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any LIMN yet.
Related Tickers
Earnings